New hope for lung cancer: first human trial of DZD6008 begins
NCT ID NCT06813365
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This early-stage trial tests a new drug called DZD6008 in about 190 people with advanced non-small cell lung cancer that has a specific EGFR mutation. The main goals are to check the drug's safety and see if it can shrink tumors. Because this is the first time the drug is given to humans, researchers are being very careful.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- DZD6008
- What this could lead to
- If this drug works, it could offer a new treatment option for people with advanced lung cancer that has a specific EGFR mutation.
- What could go wrong
- This is the first time DZD6008 is tested in humans, so safety and effectiveness are unknown. The trial is small and early, so many drugs at this stage do not succeed.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NONSMALL CELL LUNG CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Peking Union Medical College Hospital
RECRUITINGBeijing, Beijing Municipality, 100005, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- First-in-Class cancer drug targets Hard-to-Treat tumors
- Experimental combo for lung cancer shows promise but study cut short
- AI takes on lung cancer: can a computer match a Doctor's wisdom?
- Can we treat sicker lung cancer patients the same as healthier ones?
- Electric field therapy extends life in advanced lung cancer trial
- New immunotherapy shows promise against lung cancer in major trial